The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy
Biomolecules · 12.11.2025 · 15 (11) · 1586
DOI: 10.3390/biom15111586 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 12.11.2025. Verfasst von Ryuhei Ishihara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. Hauptthemen laut MEDLINE: Interferon Type I, Autoimmune Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 418 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Type I interferons (IFN-I) are pivotal effectors of innate immunity and constitute a central axis of host defense against pathogens. Sensing of exogenous or endogenous nucleic acids by pattern-recognition receptors—exemplified by Toll-like receptors—triggers transcriptional induction of IFN-I. Engagement of the heterodimeric IFN-I receptor on nucleated cells reprograms cellular states via canonical Janus kinase–signal transducer and activator of transcription (JAK–STAT) signaling as well as STAT-independent, noncanonical pathways. This axis is tempered by multilayered regulatory mechanisms, including epigenetic remodeling, and important aspects remain incompletely defined. Dysregulation of IFN-I activity underlies diverse autoimmune disorders, notably systemic lupus erythematosus, wherein IFN-responsive gene signatures stratify disease endotypes, reflect disease activity trajectories, and predict therapeutic responsiveness. In recent years, therapeutic strategies targeting this pathway are now available: anti-IFN-I receptor therapy for systemic lupus erythematosus (SLE) and JAK inhibition for rheumatoid arthritis (RA) and giant cell arteritis (GCA). Altogether, a refined understanding of the IFN-I axis furnishes a pragmatic framework for patient stratification, response prediction, and mechanism-informed therapy design across immune-mediated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
- Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki 660-8550, Japan.
ORCID-Profile: Ryu Watanabe, Masao Katsushima, Kazuo Fukumoto
Zitieren
APA
Ishihara, R., Watanabe, R., Shiomi, M., Fujita, Y., Katsushima, M., Fukumoto, K., Yamada, S., & Hashimoto, M. (2025). The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy. Biomolecules, 15(11), 1586. https://doi.org/10.3390/biom15111586
Vancouver
Ishihara R, Watanabe R, Shiomi M, Fujita Y, Katsushima M, Fukumoto K, et al. The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy. Biomolecules. 2025;15(11):1586. doi:10.3390/biom15111586
BibTeX
@article{Ishihara2025,
author = {Ishihara, Ryuhei and Watanabe, Ryu and Shiomi, Mayu and Fujita, Yuya and Katsushima, Masao and Fukumoto, Kazuo and Yamada, Shinsuke and Hashimoto, Motomu},
title = {The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {11},
pages = {1586},
doi = {10.3390/biom15111586}
}
EUVIMED